The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Biocryst Pharmaceuticals Inc shares valued at $54,352 were sold by McKee Amy E on Jun 24 ’24. At $6.32 per share, McKee Amy E sold 8,600 shares. The insider’s holdings dropped to 27,831 shares worth approximately $0.22 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, SANDERS MACHELLE sold 4,689 shares, netting a total of over 28,134 in proceeds. Following the sale of shares at $6.00 each, the insider now holds 27,742 shares.
Before that, HEGGIE THERESA had sold 6,698 shares from its account. In a trade valued at $40,925, the Director traded Biocryst Pharmaceuticals Inc shares for $6.11 each. Upon closing the transaction, the insider’s holdings decreased to 6,698 shares, worth approximately $0.41 million.
Analysts at RBC Capital Mkts upgraded the stock from ‘”a Sector perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid September. As of August 04, 2023, Jefferies has increased its “Hold” rating to a “Buy” for BCRX. Earlier on July 13, 2023, BofA Securities upgraded its rating. Their new recommendation was “a Buy” for BCRX stock which previously was a “a Neutral”.
Analyzing BCRX Stock Performance
During the last five days, there has been a drop of approximately -7.65%. Over the course of the year, Biocryst Pharmaceuticals Inc shares have jumped approximately 29.05%. Shares of the company reached a 52-week high of $8.88 on 09/03/24 and a 52-week low of $4.03 on 04/25/24. A 50-day SMA is recorded $7.80, while a 200-day SMA reached $6.45. Nevertheless, trading volume fell to 3.5 million shares from 4.09 million shares the previous day.
Support And Resistance Levels for Biocryst Pharmaceuticals Inc (BCRX)
According to the 24-hour chart, there is a support level at 7.31, which, if violated, would cause prices to drop to 6.88. In the upper region, resistance lies at 7.95. The next price resistance is at 8.16. RSI (Relative Strength Index) is 49.59 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.51, which suggests the price will decrease in the coming days. Percent R is at 44.51%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
